Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

FDA proposes once-a-year COVID-19 shots for most Americans

Por: Los Angeles Times Science January 24, 2023

thumbnail

U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot. The Food and Drug Administration on Monday proposed a simplified approach for future vaccination efforts, allowing most adults and children to get a once-a-year shot to protect against the mutating virus. This means Americans would no longer have to keep track of how many shots they’ve received or how many months it’s been since their last booster. The... + full article



Similar News

Health Care — FDA committee votes to change vaccine strategy

The Hill USA Health January 27, 2023

thumbnailA key FDA committee voted to update the current vaccination strategy against COVID-19, signaling a shift in how the U.S. will handle the virus going into the fourth year of the pandemic.  Welcome to The Hill’s Health Care roundup, where we’re following the latest moves on... + más

Change to Covid vaccine formulation signals start of FDA pivot in immunization strategy | Politico

Best TV Show bracket: Here’s how you voted in Rounds 1 and 2 | The Boston Globe


House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug

Politico USA Health December 30, 2022

thumbnailThe FDA’s collaboration with Biogen, the maker of a controversial Alzheimer’s drug, before it granted the product accelerated approval was “atypical” and ran afoul of the agency’s protocol for documenting interactions with drug companies, according to a joint House... + más

Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times

Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News


FDA Approval of Alzheimer's Drug Was 'Rife With Irregularities': Congressional Report

NBC 6 South Florida USA World December 30, 2022

thumbnailAdam Glanzman Bloomberg Getty Images The ’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed... + más

Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times

FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial | CNBC


Panel warns FDA’s beleaguered tobacco unit lacks direction

ABC News USA Health December 20, 2022

thumbnailWASHINGTON -- The lack of clear direction and priorities at the U.S. Food and Drug Administration's tobacco division has hampered its ability to regulate electronic cigarettes and other products, according to an expert panel assembled to examine problems at the agency.A... + más

Panel warns FDA’s beleaguered tobacco unit lacks direction | Associated Press

Panel warns FDA’s beleaguered tobacco unit lacks direction | WPLG Local 10


Panel warns FDA’s beleaguered tobacco unit lacks direction

WPLG Local 10 USA Politics December 20, 2022

thumbnailWASHINGTON – The lack of clear direction and priorities at the U.S. Food and Drug Administration's tobacco division has hampered its ability to regulate electronic cigarettes and other products, according to an expert panel assembled to examine problems at the agency.A... + más

Panel warns FDA’s beleaguered tobacco unit lacks direction | ABC News

Panel warns FDA’s beleaguered tobacco unit lacks direction | Associated Press


Panel warns FDA’s beleaguered tobacco unit lacks direction

Associated Press USA Politics December 19, 2022

thumbnailWASHINGTON (AP) — The lack of clear direction and priorities at the U.S. Food and Drug Administration’s tobacco division has hampered its ability to regulate electronic cigarettes and other products, according to an expert panel assembled to examine problems at the agency.A... + más

Panel warns FDA’s beleaguered tobacco unit lacks direction | ABC News

Panel warns FDA’s beleaguered tobacco unit lacks direction | WPLG Local 10


ALS drug wins FDA approval despite questionable data

ABC News USA Health September 30, 2022

thumbnailWASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | WPLG Local 10



About iurex | Privacy Policy | Disclaimer |